CREXONT ER
ApprovedSmall molecule
CREXONT ER is one of 46 small molecule programs targeting Parkinson disease. It is currently in Approved.
1
Indications
2
Total Trials
2
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
165 competitors in Parkinson Disease
#DrugCompanyPhaseTrials
1Vesicare
AstellasPhase 3
Byetta
AstraZenecaPhase 3
Mirapex
Boehringer IngelheimPhase 3
Avicel
SSanthera Pharmaceuticals
Phase 3
Allegra
CChattem
Phase 3
Xifaxan
SSalix
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Wakix
HHarmony Biosciences Management, Inc.
Phase 3
XEOMIN
MMerz Pharmaceuticals GmbH
Phase 3
Levodopa/carbidopa
Orion Corporation, Orion PharmaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Parkinson's Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CREXONT ER. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- TThe Cleveland Clinic